Norway Women’s Health Market Size & Outlook, 2023-2030
Norway women’s health market, 2018-2030 (US$M)
Related Markets
Norway women’s health market highlights
- The Norway women’s health market generated a revenue of USD 122.4 million in 2023 and is expected to reach USD 181.5 million by 2030.
- The Norway market is expected to grow at a CAGR of 5.8% from 2024 to 2030.
- In terms of segment, contraceptives was the largest revenue generating application in 2023.
- Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
Women’s health market data book summary
| Market revenue in 2023 | USD 122.4 million |
| Market revenue in 2030 | USD 181.5 million |
| Growth rate | 5.8% (CAGR from 2023 to 2030) |
| Largest segment | Contraceptives |
| Fastest growing segment | Endometriosis & Uterine Fibroids |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, Norway accounted for 0.3% of the global women’s health market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany women’s health market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 3,031.4 million by 2030.
Contraceptives was the largest segment with a revenue share of 33.01% in 2023. Horizon Databook has segmented the Norway women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing women population aged 65 & above in the country is boosting the prevalence of targeted disease, which is creating new opportunities for market stakeholders. According to World Bank, in 2022, the women population aged 65 and above in Norway was more than 533,000, and it is expected to increase in the coming years.
Moreover, according to WHO, the prevalence of osteoporosis ranged from 14% to 36% in Norwegian women aged above 59. Global companies are entering and expanding their horizon into women's health space to leverage lucrative opportunities in the women's health market.
The company developed its distribution network across Europe, including countries such as Norway. Such strategic initiatives by market players are anticipated to fuel market growth in the country. Moreover, favorable initiatives undertaken by government bodies to improve women's health are anticipated to support the overall market growth.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Women’s Health Market Scope
Women’s Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway women’s health market size, by application, 2018-2030 (US$M)
Norway Women’s Health Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
